Medicine and Dentistry
Neoplasm
100%
Melanoma
84%
Tumor Cell
63%
Malignant Neoplasm
63%
Melanoma Cell
60%
Diseases
57%
Cancer
40%
Breast Cancer
34%
Metastatic Carcinoma
33%
In Vitro
33%
Cancer Cell
31%
Wilms' Tumor
28%
Pediatrics
25%
Oncologist
23%
Oncology
23%
Overall Survival
21%
COVID-19
21%
Metastatic Melanoma
21%
Cell Invasion
19%
Infection
18%
Tumor Progression
17%
Prostate Cancer
17%
Pancreas Cancer
15%
Cell Line
15%
Awareness
15%
Immunotherapy
14%
Pathologist
14%
Maspin
14%
Basement Membrane
14%
Endothelial Cell
13%
Lung Cancer
13%
Virus
13%
Gene Expression
13%
Extracellular Matrix
12%
Radiation Therapy
12%
Morphology
12%
Quality of Life
11%
Kidney Tumour
11%
Vimentin
11%
Cell Signaling Pathway
11%
Nodal Signaling
11%
Uterine Cancer
11%
Ovarian Cancer
11%
Angiogenesis
11%
Magnetic Resonance Imaging
11%
Biological Marker
11%
Clinical Trial
11%
Stem Cell
10%
Targeted Therapy
10%
Cancer Therapy
10%
Health Care
10%
Programmed Cell Death
10%
Cell Migration
10%
Carcinogenesis
10%
Pancreas Adenocarcinoma
10%
Symptomatic Treatment
10%
Clinician
10%
Severe Acute Respiratory Syndrome Coronavirus 2
10%
Immune Checkpoint Inhibitor
9%
Adverse Event
9%
Cell Plasticity
9%
Gelatinase A
9%
Chemoradiotherapy
9%
Adenocarcinoma
9%
Health Care Cost
9%
Breast Carcinoma
9%
Melanocyte
9%
Agar
9%
Systematic Review
9%
Monoclonal Antibody
8%
Uvea Melanoma
8%
Melanoma Cell Line
8%
Odds Ratio
8%
Melanoma Skin Cancer
8%
Prevalence
8%
Retrospective Study
8%
Promoter Region
8%
Progression Free Survival
8%
Biopsy Technique
8%
Integrin
8%
Keratin
8%
Epithelial Cell
8%
Morphogen
8%
Clear Cell Renal Cell Carcinoma
7%
Hypoxia
7%
Lung
7%
Glioblastoma
7%
Tumor Microenvironment
7%
Recurrent Disease
7%
Immunohistochemistry
7%
Female Genital Tract Cancer
7%
T Cell
7%
Metastasis Potential
6%
Organ Donor
6%
Neoadjuvant Chemotherapy
6%
Metastatic Breast Cancer
6%
Neoadjuvant Therapy
6%
Health Behavior
6%
Doxorubicin
6%
Logistic Regression Analysis
6%
Keyphrases
Melanoma
55%
Tumor
52%
Melanoma Cells
49%
Tumor Cells
47%
Human Melanoma Cells
36%
Metastatic Melanoma
31%
Vasculogenic Mimicry
31%
Wilms Tumor
31%
Chicago
27%
Maspin
25%
Dip-pen Nanolithography
24%
Electron-nuclear Double Resonance (ENDOR)
22%
Caenorhabditis Elegans
21%
In Cancer
21%
Peritoneal Surface Malignancy
20%
Confidence Interval
20%
Gene Expression
19%
United States
19%
Overall Survival
19%
COVID-19
18%
Cell Invasion
18%
Monoclonal Antibody
18%
Prostate Cancer
18%
Oligonucleotides
17%
Breast Cancer
17%
Cancer Cells
16%
Signaling Pathway
15%
Vimentin
15%
Microenvironment
15%
Chemotherapy
14%
Aggressive Tumor
14%
Cancer Patients
14%
Breast Cancer Cells
13%
Phase II Trial
13%
Pathologist
13%
Human Melanoma
13%
Parkinson's Disease
13%
Transcription Factor
13%
Tumor Progression
13%
Women's Health Initiative
13%
Cripto-1
12%
Nuclear Respiratory Factor 1 (NRF1)
12%
Tumor Cell Invasion
12%
Nodal Signaling
12%
Clinical Trials
12%
Angiogenesis
11%
Metastasis
11%
Metastatic Breast Cancer
11%
Glioblastoma
11%
Intermediate Filaments
11%
Trend Analysis
11%
Longitudinal Trends
11%
Lung Cancer
11%
Solid Organ Transplant Recipients
11%
Colorectal Cancer
11%
Macrocycles
11%
Immune Checkpoint Inhibitors
11%
Q-band
11%
Influenza
11%
Hypoxia
11%
Culture System
11%
Extracellular Matrix
11%
Monoamine Oxidase B (MAO-B)
11%
Ovarian Cancer
11%
Melanoma Tumor Cells
10%
A375P
10%
Invasive Potential
10%
Children's Oncology Group
10%
Epithelial Cells
10%
Metastatic Potential
10%
Clinical Outcomes
10%
Reconstituted Basement Membrane
10%
Randomized Controlled Trial
10%
Surgical Oncologist
10%
Motility
10%
Human Embryonic Stem Cells (hESCs)
10%
Aminobutyric Acid
10%
Cutaneous T-cell Lymphoma
10%
Type IV Collagen
10%
Radiologists
10%
Non-small Cell Lung Cancer (NSCLC)
10%
Progesterone Receptor
10%
Desmoplakin
10%
Medical Oncologist
10%
Enhanced Awareness
10%
Targeted Therapy
10%
Favorable Histology
10%
Older Adults
9%
Porphyrazine
9%
Pharmacist
9%
Appropriate Management
9%
Palliative Care Physicians
9%
Peritoneal Surface Disease
9%
Methylation
9%
Integrin
9%
Virus
9%
Quality of Life
9%
Physical Activity
9%
Pancreatic Cancer
9%
Oncology
9%